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Abstract
Background: Due to the controversy over the effect of serum testosterone levels on
coronary artery diseases, this survey explores the serum levels of free testosterone,
luteinizing hormone, and follicle-stimulating hormone in candidates for coronary
artery bypass graft compared with an age-matched control group and evaluates the
associated factors in these participants.
Objective: To determine the testosterone level in elective coronary artery bypass
grafting participants.
Materials and Methods: In this cross-sectional study, all male patients aged > 40 yr
as candidates for elective coronary artery bypass grafting, who were referred to the
Afshar Hospital, Yazd, Iran, from March 2018 to March 2019, were included. In total,
100 men were enrolled (50 cases and 50 controls). Their serum levels of free and total
testosterone, luteinizing hormone, and follicle-stimulating hormone were measured
and the results were compared.
Results: The findings indicated a significant difference between the two groups in total
and free testosterone (both p < 0.001); they were lower in the case group. There was
also a significant difference in the total testosterone of the participants with diabetes
mellitus comparedwith no-diabetic individuals (p = 0.007). Free testosterone of diabetic
subjects taking insulin was lower compared with those taking no insulin (p = 0.04).
There was also an association between the body mass index and free testosterone,
left ventricular ejection fraction and total testosterone, and a significant and negative
relation between the duration of hospital admissions and free testosterone (p < 0.05).
Conclusion: This study illustrates that participants with coronary artery disease bear a
significantly low testosterone level in comparison with the healthy control group.
Key words: Coronary artery disease, Testosterone, Coronary artery bypass graft
surgery.
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1. Introduction
Over the past decades, the pattern of the most
common fatal diseases in adults has changed from
communicable to non-communicable diseases,
of which cardiovascular diseases (CVDs) appear
to be highly important with regard to global
mortality as well as disease burden (1). As
estimated, in 2016, about 40.5 million worldwide
deaths (71%) emerged from non-communicable
diseases, 80% of which emanated from cancers,
CVDs, chronic respiratory diseases, and diabetes
mellitus (DM) (2); however, interestingly, about half
of these cases have arisen from CVDs alone (3).
Although several strategies have been suggested
to shrink the mortality rate of CVDs resulting
in 39% decrease in the age-related mortality,
the global deaths from CVDs have increased by
41% over the past two decades (from 1990 to
2013), primarily as a result of population growth
(resulting in 55% increase in the mortality rate)
and population aging (resulting in 25% increase
in the mortality rate) (4). Accordingly, research has
been advanced toward the risk factors of CVDs,
specifically coronary artery diseases (CADs) as
the main cause of mortality of CVDs in order to
develop the preventive strategies for CVDs (5,
6).
Moreover, studies on the risk factors of
myocardial infarction (MI) and CVDs have touched
upon the participants’ sex as a critical and
determinant indicator (7). It has been identified
that women experience their first MI about
10 years later than men, while this difference
appears to attenuate after menopause (8). A body
of evidence also suggests that this difference
projects likely as the result of altered immune
response during atherosclerosis triggered by sex
hormones (9). Androgenic hormones may play a
significant role in the onset and progression
of CVD in men as testosterone produces
vasorelaxation, improves the endothelial
function, and has an atheroprotective effect
resulting in a lower risk of MI in older men
after andropause (10, 11). However, results of a
meta-analysis suggest the controversy on the
effect of testosterone-replacement therapy
on older men around the incidence of MI
(12).
On the basis of these controversial results, the
study of the association of serum levels of free T
with CADs appears to be necessary. In Iran, the
incidence rate of MI in men seems to be three
times higher than in women but the effect of sex
hormones on the risk of MI remains yet to be
known (13).
This study, therefore, deals with a survey
concerning the serum levels of free testosterone,
luteinizing hormone (LH), and follicle-stimulating
hormone (FSH) in participants who were
candidates for coronary artery bypass graft
(CABG) compared with an age-matched control
group.
2. Materials and Methods
2.1. Study design
In this cross-sectional study, all male
participants who were candidates for elective
CABG and were referred to the Afshar-Yazd
Hospital, Yazd, Iran, between March 2018 and
March 2019 were considered as the study
population. The sample size was calculated
as 50, considering 95% confidence interval
(CI), ± 1 SD for serum-free testosterone, and
1.1 unit error. The participants meeting the
inclusion criteria of the study were included
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using the consecutive method. The inclusion
criteria comprised of male participants aged
> 40 yr; candidates for elective CABG during
the study period. Those who did not have
any positive history of MI; emergency CABG,
testicular surgery or tumor, chemotherapy,
hepatorenal failure; and did not show any
history of taking exogenous testosterone
or any other hormonal drugs such as
finasteride and flutamide were excluded.
Also, we had a control group including 50
participants with no history of coronary artery
diseases.
Personal particulars of the participants were
recorded through a checklist designed for data
collection including participants’ demographics
such as age, body mass index (BMI), history
of diseases including DM, hypertension (HTN),
hyperlipidemia (HLP), smoking, drug abuse, as
well as taking aspirin, beta-blockers, statins, and
insulin. Before surgery, a venous blood sample
was taken from all participants after 12 hr of fasting
in a sitting position. The blood samples were
obtained and transferred to the hospital laboratory
immediately. The blood samples were centrifuged
at 3000 rpm for 5 min at room temperature
using a SELECT LAB (Model: TD25-WS, Lu
Xiangyi, China). The serum levels of free and
total testosterone, LH, and FSH were measured
in the lab using ELISA test. To measure FSH
and LH, LIASON instrument (Type: 2229, Liaison
Diasorin, Germany) was used. The normal range
of the kits was 2.8-6.8 mIU/mL for LH and 1.3-11.8
mIU/mL for FSH. The total and free testosterone
were measured by MINDRAY microplate ELISA
reader (Model: MR-96A, Mindray, Germany). The
normal range of the kits was 2-11 ng/mL for
total testosterone and 5.7-30.7 pg/mL for free
testosterone.
Of note, all participants underwent
echocardiography and angiography; however,
we did not record the severity of coronary
artery involvement as we did not have access to
films. After the surgery, hemodynamic instability
(BP < 60 mmHg, the need to adrenalin > 0.1
µg/kg/min, or noradrenalin > 0.01 µg/kg/min,
and/or dobutamine > 8 µg/kg/min), as well as
mechanical support (intra-aortic balloon pump)
and cases of death during hospital admissions
were extracted from the participants’ medical
records.
The results were finally compared with the
control group comprising of 50 participants with
no history of coronary artery diseases referred to
the same laboratory.
2.2. Ethical considerations
This study was approved by the
ethics committee of the Shahid Sadoughi
University of Medical Sciences in Yazd, Iran
(IR.SSU.MEDICINE.REC.1395.252). All participants
were informed about the study design and
objectives and had signed a written informed
consent form prior to the study.
2.3. Statistical analysis
The results of the numerical variables are
presented as mean ± standard deviation (SD)
and compared between the groups using t test
or Mann-Whitney U test whenever the data
failed to show normal distribution or when the
assumption of the equal variances was violated
across the study groups. Categorical variables
were reported by a number (percentage) and
compared between the groups using Chi-square
test. For comparison, the total T levels of the
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case group were categorized into three groups:
< 2 ng/mL (lower limit normal: group A), 2-
7.5 ng/mL (group B) and 7.6-11 ng/mL (group C)
while similarly free testosteronewas classified into
three levels according to their values: < 5.7, 5.7-
18.2, and 18.3-30.7 ng/mL as groups A-C. The
association of variables was tested by Pearson’s or
Spearman’s correlation coefficient. For statistical
analysis, IBM SPSS for Windows version 22.0 (IBM
Corp. 2013. Armonk, NY: IBM Corp.) was used.
P-values < 0.05 were considered as statistically
significant.
3. Results
Of the 100 participants included in this study,
50 were evaluated as the case and 50 as the
controls. The mean ± SD of the participants’ age
in the case and control groups turned out to be
61.5 ± 8.48 years (range: 42-79 yr) and 61.72 ±
8.37 yr, respectively; no significant difference was
thus identified in this regard (p = 0.896). Moreover,
no significant difference could be found between
the mean ± SD of the participants’ BMI in the
groups (28.46 ± 19.5 vs 25.61 ± 3.95 kg/m2; p =
0.313).
Of the 50 participants in the case group,
45 underwent off-pump CABG and five were
treated with on-pump CABG. The mean ± SD of
the participants’ left ventricular ejection fraction
(LVEF) in the case group was 43.90 ± 8.09
(25-60%). The frequency of positive underlying
diseases in the case group was as follows: 46%
had DM, 34% HTN, 36% HLP, 26% were currently
smoking, and 26% had drug abuse. Considering
the medical history, 54% had a positive history
of using beta-blockers, 66% statins, and 8%
antidiabetes drugs. After the surgery and in the
intensive care unit (ICU), 4% required a balloon
pump and 30% were in need of inotropes with
no fatality. The mean ± SD of hospitalized
participants in the case group was 5.6 ± 1.3
(range: 4-11) days, that in the ICU was 3.6 ±
0.9 (range: 2-7) days, and that of the intubation
period proved to be 5.01 ± 0.60 (range: 3-21)
hr.
Comparing the mean values of free and total
testosterone between the participants with and
without any underlying disease and medical
history of drug-taking using t test illustrated a
significant difference in the total testosterone of
the participants with DM (p = 0.007) and in the
free testosterone of the patients with a history
of taking insulin (p = 0.04) (Table I). Studying the
correlation between the variables revealed
a significant positive relationship between
the BMI and free testosterone (p = 0.023),
LVEF and total testosterone (p = 0.02), and a
significant but negative association between
hospitalization and free testosterone (p = 0.026)
(Table II).
As set out in Table III, comparing the serum
parameters between the case and control
groups using t test indicated no difference in
the mean values of LH (p = 0.418) and FSH
(p = 0.519), while a significant difference was
identified between the groups in terms of
mean values of total and free testosterone
(p = 0.001).
Categorizing participants’ total testosterone
into three groups revealed 13 participants
belonging to group A level of total testosterone,
36 to group B, and only one patient to group C.
Also categorizing participants’ free T into three
groups in the cases revealed 20 participants
being in group A level of free T, 30 others in
group B, while no participant was found to be in
group C.
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Table I. Comparison of the mean values of free and total testosterone according to the participants’ medical history in the case
group





Positive 23 2.37 ± 1.34 6.88 ± 3.43Total diabetes mellitus




Positive 13 2.81 ± 1.35 6.99 ± 3.01Hypertension




Positive 14 3.44 ± 1.44 7.58 ± 3.28Hyperlipidemia




Positive 13 3.00 ± 2.45 7.14 ± 4.37Smoking




Positive 13 2.63 ± 1.17 6.65 ± 3.92Substance abuse




Positive 17 3.36 ± 1.69 6.59 ± 3.17Aspirin




Positive 27 2.86 ± 1.42 7.39 ± 3.19Beta-blockers




Positive 33 3.05 ± 1.42 7.35 ± 3.21Statins




Positive 4 1.82 ± 0.43 4.11 ± 1.56Insulin




Positive 15 2.97 ± 1.36 6.96 ± 3.45Inotrope




Positive 48 2.71 ± 0.73 6.04 ± 1.92Intra-aortic pump




Data presented as Mean ± SD. To compare variables, t test was used








BMI r = 095p = 0.511 – – – – – –
Total testosterone r = –0.089p = 0.540
r = –0.002
p = 0.989 – – – – –




p = 0.026 – – – –



















p = 0.861 – –



























Values show the Pearson’s correlation coefficient and p-values were considered significant when < 0.05
BMI: Body mass index, LVEF: Left ventricular ejection fraction, ICU: Intensive care unit
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LH 6.38 ± 5.97 7.01 ± 6.34 0.418
FSH* 11.34 ± 13.33 10.75 ± 9.13 0.519
Total testosterone (ng/mL) 3.03 ± 1.63 4.16 ± 1.31 0.001
Free testosterone (ng/mL) 7.36 ± 3.45 11.26 ± 4.08 0.001
Data presented as Mean ± SD for continuous variables, t test was used to compare the continuous variables, LH: Luteinizing
hormone, FSH: Follicle-stimulating hormone
*Median (Interquartile Range); Case: 7 (4.39-13.57), Control: 7.88 (5.82-11.52)
4. Discussion
The results of this study suggested the serum
level of free and total testosterone in the group
candidate for CABG being significantly lower
compared with the control group. We included
all participants > 40 yr to reduce the chance of
genetic factors inducing CAD which are usually
observed at younger ages. Furthermore, we
did not include the patients with recent MI
or any other major stress so as to eliminate
the effect of this factor on the androgen-level
change. The results of our study indicated
no patient in the case group having upper-
limit total or free testosterone or between mid-
range and upper-limit free testosterone. These
results suggest that participants with CAD bear
a lower level of testosterone with regard to
their age and BMI matched with the control
group, thereby confirming the results reported
by other researchers who suggest lower level of
serum testosterone in middle-aged men with CAD
including the participants with stable or unstable
angina pectoris or acute MI (14).
In an Iranian study, Allameh and colleagues
evaluated 200 participants in the CAD group and
135 individuals in the control group and reported
significantly higher dehydroepiandrosterone
sulfate (DHEA-S) and testosterone levels in the
control group (15), hence being in line with our
results. In their study, the serum testosterone
level appeared to be 0.47 ± 0.65 ng/mL in the
participants with atherosclerotic coronary arteries
(N = 35), 0.04 ± 0.08 ng/mL in those with the
history of acute MI (N = 30), and 1.12 ± 0.29 ng/mL
in healthy subjects (N = 30) (15).
In another study, Malkin and colleagues
suggested that testosterone deficiency is a
common finding in participants with CAD, being
inversely associated with their survival (16); this is
consonant with the results of the present study as
we too did not notice any patient with an upper-
limit total or free testosterone or between mid-
range and upper-limit free testosterone levels.
Although a number of aforementioned studies
(14-16) have confirmed our findings in terms of
lower testosterone levels in the participants with
CAD, other studies have reported no difference
in the DHEA-S and serum testosterone levels
between the case and control groups (17, 18).
In addition to the controversial results regarding
the different testosterone values between the
participants with CAD and the control group, the
association of androgens with the severity of
CAD also needs to be tackled. In a study by Hu
and colleagues the authors concluded a negative
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correlation between the serum testosterone and
the severity of coronary artery stenosis (14).
However, Allameh and colleagues detected no
association between the androgenic hormone
levels and the risk of CAD (15). In the present
study, we did not have access to angiographic
assessment results to indicate the association
between the serum testosterone and the severity
of CAD. Even the results of meta-analysis on this
issue have failed to project any definite results
(19). However, one meta-analysis concluded the
results of studies published before and after
2007 being different. Recent studies suggest that
endogenous testosterone is not associated with
the risk of CVD in middle-aged men, and instead
may poorly protect the elderly against CVD (20).
However, we did not separate the results of
the elderly although we included the participants
aged > 40 yr to reduce the confounding effect
of age on the results. To balance, it is well-
known that T has vasoactive properties and it
is not easy to rule out the low testosterone in
the participants with CAD, which suggests the
discrepancy in the results attributed to different
laboratory measurements, definitions of CAD, as
well as the notion that serum testosterone levels
may not represent the true serum androgen level
(21). Furthermore, several factors may affect the
serum testosterone levels that can impact the
results (22).
Pieces of evidence suggest the effect of
underlying diseases including dyslipidemia,
obesity, and DM on the serum testosterone (23,
24). Therefore, in this study we made an attempt
to examine the difference in testosterone values
based on several diseases such as DM, HTN, and
HLP, and the results demonstrated the mean total
testosterone levels of the participants with DM
and the mean free testosterone of the participants
taking insulin being lower than those without. The
association of T and DM has also been suggested
in previous studies (15, 25), which confirms the
results of the present study. Also, lower mean
testosterone in the participants who receive
insulin confirms the association of diabetes with
testosterone and is consistent with the results of
the previous studies suggesting the relationship
between insulin resistance and low testosterone
levels (26-28).
Furthermore, the results of logistic regression
in our study exhibited a positive association
between BMI and free testosterone, between
LVEF and total testosterone, and a negative
association between the duration of hospital
admissions and free testosterone. The
relationships between BMI and testosterone
levels have also been discerned in previous
studies on healthy individuals. However, they
have mainly reported an inverse relationship
as obese men seem to have a lower serum
testosterone level (29). This effect is attributed to
the fact that higher testosterone induces more
muscle mass and lower fat mass while DHEA-
S also lowers lipid accumulation and triggers
lipolysis (30). However, in the present study,
an investigation of the association of BMI with
testosterone levels in the participants with CAD
revealed a positive correlation between BMI and
free testosterone, but not total testosterone.
Furthermore, higher total testosterone levels
were positively associated with LVEF, and
higher free testosterone levels led to shorter
hospitalization which confirms the beneficiary
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effect of testosterone on the participants’ survival
as suggested previously (16). Nevertheless,
in our study, no death was reported during
the admission to enable us to investigate the
difference in the mortality or survival rate of
the participants on different testosterone levels.
Meanwhile, the duration of hospital stay or
ICU admission failed to be associated with the
testosterone levels.
This study investigated the difference in
testosterone levels among the participants with
CAD compared with a control group to indicate
the effect of serum testosterone levels on CAD.
However, this study had some limitations: firstly,
the participants enrolment in this study were non-
randomized, thus increasing the chance of bias
in the results; secondly, we had no access to the
information of the participants in the control group
as we added this group after the completion of
the study using laboratory results; and thirdly,
we only measured the serum values of FSH,
LH, and free and total testosterone but not of
other hormones such as DHEA-S, estradiol, and
sex-hormone-binding-globulin. Moreover, we did
not have access to the angiographic results of the
participants to investigate the difference in serum
testosterone levels according to the severity of
CAD in the participants.
5. Conclusion
The results of the present study demonstrated
that participants with CAD bear a significantly low
Testosterone level in comparison with the healthy
control group as well as the association of the
serum T levels with LVEF and negative relation
with a hospital stay even though we observed
no case of death in our study to investigate the
exact effect of serum T levels on the participants’
survival. Future studies with longer follow-up
periods are required for the investigation of
the effect of androgens on the survival of the
participants with CAD and the difference in serum
testosterone levels with regard to the severity of
CAD.
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